Biofilm

Temple University School of Podiatric Medicine's picture
Temple University School of Podiatric Medicine

Temple University School of Podiatric Medicine Journal Review Club

Delayed healing in diabetic foot ulcers (DFUs) is the result of the polymicrobial structures of DFUs and the buildup of biofilms. Wound debridement is an essential part of wound bed preparation (WBP) that helps to remove bacteria and allow the body to continue the healing process. Although sharp debridement is the most common technique used for DFUs, it has many limitations, including contraindications in patients with poor vascular status, the need for an operating room, and the requirement for specific surgeon skills. There is also the potential for extensive damage to the wound bed with exposed bone because of obstruction of the view from biofilm formation. The use of an ultrasound-assisted wound (UAW) debridement device aims to disrupt the formation of biofilms and stimulate wound granulation, thus allowing for the wound to have a healthy environment in which to heal. This study evaluated the clinical and microbiological impact of using UAW debridement devices in individuals with neuroischemic DFUs.

Blog Category: 
WoundSource Practice Accelerator's picture

By the WoundSource Editors

Caseous necrosis: Caseous necrosis is found in tuberculosis, syphilis, and some fungal diseases. It forms in response to intracellular pathogens, such as mycobacteria, and can also be found in association with granulomas. With this type of cell death, the tissue assumes a cheese-like appearance.

Clostridium difficile: Also referred to C. diff, this bacterium can cause symptoms ranging from diarrhea to life-threatening inflammation of the colon. On a lesion, semihard nodules may be found, in which case lymph node tuberculosis may be present.

Complex wounds: Wounds that have one or more complicating factor, such as exudate, infection, comorbidity, or polypharmacy. They can be acute or chronic wounds that defy cure with conventional therapies. Treating complex wounds generally requires a multidisciplinary approach.

WoundSource Practice Accelerator's picture
Biofilm

By the WoundSource Editors

Biofilm: this term is frequently used in the wound care space, but biofilm continues to be largely undertreated in wound care. What do the bedside nurse or clinician need to know about biofilm? Should clinicians care less about biofilm on a maintenance or palliative wound versus a wound they are actively trying to heal? Let's address these questions and get to the root of the biofilm in managing complex wound cases.

Gregory Schultz's picture
Biofilm Frequently Asked Questions

By Gregory Schultz, PhD

In my recent WoundSource webinar on the assessment and treatment of chronic wounds and biofilms, I discussed the pathogenesis of chronic wounds and offered a biofilm-based wound care protocol to promote healing.

WoundSource Practice Accelerator's picture
biofilm development stages

by the WoundSource Editors

Advancements in molecular microbiology, microscopy technology, and techniques for study of bacteria have increased the ability to identify the existence of biofilms, but there still remains the unknown, such as differentiating between planktonic bacteria and biofilm.1 Chronic non-healing wounds harbor bacteria across the wound etiology classification.2–4 Malone et al. determined that the prevalence of biofilms in chronic wounds was 78.2% (confidence interval, 61.6–89, P < 0.002).2 The development of biofilms moves through a common pattern: attachment, microcolony formation, maturation, and dispersion. The initial attachment is reversible, but the attachment becomes stronger as cells multiply and change their gene expressions. This cell communication process is referred to as quorum sensing, allowing cells to survive.

WoundSource Practice Accelerator's picture
wound biofilm virulence

By the WoundSource Editors

Wound biofilms not only impede healing but also increase the risk of infection. It is essential that wound biofilms be addressed and treated in a prompt, consistent manner. Biofilms have been an ongoing challenge because of the majority of resistant bacteria. Research in antibiofilm technology continues to grow, and it is essential to keep up on the most recent evidenced-based practice literature for improving patients’ outcomes.

WoundSource Practice Accelerator's picture
skin microbiome

by the WoundSource Editors

The human skin microbiome is incredibly diverse and can contain up to one billion microorganisms on a single square centimeter, including bacteria, fungi, viruses, and arthropods. These dynamic environments often become more complicated when wounds are present, and the types of microorganisms present near the dead and damaged tissue reduce the ability to eliminate them through normal immune responses and with standard antimicrobials.

WoundSource Practice Accelerator's picture

by the WoundSource Editors

Aerobic microorganisms: Organisms thriving in an oxygen-rich environment.

Anaerobic microorganisms: Organisms thriving in an oxygen-depleted environment.

Autolytic debridement: A selective process by which endogenous phagocytic cells and proteolytic enzymes break down necrotic tissue, occurring in varying degrees in the presence of a moist wound healing environment and dependent on the patient's having a functioning immune system.

Industry News's picture

By Industry News

Pennington, NJ – March, 7 2018 – Dermalink Technologies Inc. (Dermalink) is pleased to announce the development of the first of its novel biofilm-disrupting products for the U.S. wound care market. The core ingredient, Lauroyl Arginine Ethylester (LAE), has been available in Europe for several years, where it has rapidly established itself as a proven anti-biofilm agent in the food and dental markets.

Blog Category: 
WoundSource Practice Accelerator's picture
surgical instruments for debridement

by the WoundSource Editors

One of the greatest challenges when dealing with biofilms in chronic wounds is identifying their existence in the first place. The extracellular polymeric substance or EPS on biofilms essentially is an invisible cloak that protects and hides biofilms from both the body's immune system and antimicrobial therapies. This biofilm property keeps the wound from advancing through the phases of wound healing and thus remaining in the inflammatory phase, thereby allowing further proliferation of biofilms. This is a common theme in wounds with biofilms, but other signs and symptoms will depend on the type and degree of functional impairment the host experiences. Types of inflammatory cells seen may be polymorphonuclear neutrophils, leucocytes, or mononuclear cells, but the type will depend on the predominating immune response of the host.

Blog Category: